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1. Introduction 
 Oral route is the most oldest and convenient route for the administration of therapeutic agents because of low cost 
of therapy and ease of administration leads to higher level of patient compliance. Approximately 50% of the drug products 
available in the market are administered orally and historically, oral drug administration has been the predominant route for 
drug delivery. Tablets are the most commonly and widely used dosage form. This type of drug delivery system is called 
conventional drug delivery system and is known to provide an immediate release of drug. Such immediate release (IR) 
products results in relatively rapid drug absorption and onset of accompanying pharmacodynamic effects. However, after 
absorption of drug from the dosage form is complete, plasma drug concentrations decline according to the drug’s 
pharmacokinetics profile. Eventually, plasma drug concentrations fall below the minimum effective plasma concentration 
(MEC), resulting in loss of therapeutic activity. Before this point is reached another dose is usually given if a floating longer 
therapeutic effect is desired. Conventional formulations are required to be administered in multiple doses and therefore have 
several disadvantages [1,2]. 
      Gastro retentive floating system release dosage forms have been demonstrated to improve therapeutic efficiency by 
maintenance of a steady drug plasma concentration. Floating gastro retentive prolonged release, modified release, extended 
release or depot formulations are terms used to identify drug delivery systems that are designed to achieve or extend 
therapeutic effect by continuously releasing medication over an extended period of time after administration of a single 
dose. The goal in designing floating gastro retentive system delivery system is to reduce the frequency of the dosing or to 
increase effectiveness of the drug by localization at the site of action, reducing the dose required or providing uniform drug 
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delivery. So, Gastro retentive floating dosage form is a dosage form that release one or more drugs continuously in a 
predetermined pattern for a fixed period of time, either systemically or to a specified target organ. Gastro retentive floating 
system release dosage forms provide a better control of plasma drug levels, less dosage frequency, less side effect, increased 
efficacy and constant delivery. Gastro retentive systems can remain in the gastric region for several hours and hence 
significantly prolong the gastricresidence time of drugs. Prolonged gastric retention improves bioavailability, reduces drug 
waste, and improves solubility for drugs that are less soluble in a high pH environment. To formulate a successful stomach 
specific or gastro retentive drug delivery system, several techniques are currently used such as hydrodynamically balanced 
systems (HBS) / floating drug delivery system [3], low density system [4-6], raft systems incorporating alginate gels [7-9], 
bioadhesive or mucoadhesive systems [10], high density systems [11-13], super porous hydro gels [14] and magnetic 
systems [15-17].  
Quinapril HCl (marketed under the brand name Accupril by Pfizer) is anangiotensin-converting 
enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure. A prodrug, it is 
converted to its active metabolite, quinaprilat, in the liver. Quinapril HCl inhibits angiotensin converting enzyme, an 
enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a 
powerful vasoconstrictor and increases blood pressure through a variety of mechanisms. Due to reduced angiotensin 
production, plasma concentrations of aldosterone are also reduced, resulting in increased excretion of sodium in the urine 
and increased concentrations of potassium in the blood. Quinapril HCl is indicated for the treatment of high blood pressure 
(hypertension) and as adjunctive therapy in the management of heart failure. It may be used for the treatment of 
hypertension by itself or in combination with thiazide diuretics, and with diuretics and digoxin for heart failure. Quinapril 
HCl has short half life (2 hrs). 
To reduce the frequency of administration and to improve patient compliance, gastro retentive floating system 
formulation is desirable. Quinapril HCl is a nonpeptide, non-sulfhydryl prodrug that is deesterified to quinaprilat (quinapril 
diacid), its major active metabolite following oral administration. Quinaprilat lowers blood pressure by antagonizing the 
effect of the Renin-Angiotensin-Aldosterone System (RAAS). The RAAS is a homeostatic mechanism for regulating 
hemodynamics, water and electrolyte balance.  
During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the 
granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating 
angiotensinogen to ATI, which is subsequently cleaved to ATII by Angiotensin-Converting Enzyme (ACE). ATII increases 
blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. 
Aldosterone travels to the Distal Convoluted Tubule (DCT) and collecting tubule of nephrons where it increases sodium and 
water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. 
Second, ATII stimulates the secretion of vasopressin (also known as Ant Diuretic Hormone or ADH) from the posterior 
pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the 
apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial 
vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events 
resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response 
via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-
induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of 
bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects 
of quinaprilat by causing increased vasodilation and decreased blood pressure. Peak plasma concentrations of quinapril HCl 
occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of 
quinapril HCl absorption are diminished moderately (approximately 25-30%) when Quinapril HCl tablets are administered 
during a high-fat meal. [18]  
The most commonly method of modulating the drug release is to include it in a matrix system. Because of their 
flexibility, hydrophilic polymer matrix systems are widely used in oral controlled drug delivery to obtain a desirable drug 
release profile, cost effectiveness and broad regulatory acceptance. Hence in the present work an attempt has been made to 
develop prolong release matrix tablets of Quinapril HCl using hydrophilic matrix materials like HPMC K100, K15M, and 
K4M . 
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Several gastro retentive floating formulation has been prepared for Quinapril HCl by different polymers and 
techniques. A few are described as mentioned below:  
          Vasanth et al 2013 designed the bilayer floating of tablets Quinapril Hydrochloride by direct compression method. 
The type and the concentration of the polymer are optimized to show the maximum retentive effect with good drug release 
profile. The tablets were prepared by polymers like HPMC k 100, carbopol, xanthangum, guargum. Sodium bicarbonate 
acts as gas generating agent with a view to deliver the drug at sustained manner in GIT & consequently in to systemic 
circulation. Formulations were prepared and evaluated for physical parameters & were found within prescribed limits. The 
in-vitro drug release studies were performed using USP apparatus type IІ. The drug release was dependent on the type and 
concentration of the polymer. Drug release was faster from tablets prepared with carbopol, xanthan gum and HPMC alone. 
However, in combination tablets sustained drug release effectively. The rate and mechanism of release of tablets were 
analysed by fitting the dissolution data into kinetic models. The in-vitro drug release followed zero order Kinetics and drug 
release was found to be diffusion controlled & it follows Higuchi diffusion mechanism model. It can be concluded that the 
optimized batch F6 selected as best formulation, shown buoyancy lag time of 17 sec, total floating time of 12 hrs and drug 
release of 99.636% by adopting biphasic drug release pattern in a single dosage could improve patient compliance by 
increasing the gastric retention time and give better disease management. [19]  
              Himabindu et al designed bilayer tablets of Quinapril Hydrochloride. The tablets were formulated using direct 
compression technology by employing polymers like Sodium alginate, Cekol 30000 and Kollidon SR in sustained release 
layer and crospovidone was used as super disintegrant along with other excipients. The drug-excipient compatible studies 
were performed by FTIR. The study revealed that there is no drug- excipient interaction. The prepared bilayered tablets 
were evaluated for various physicochemical parameters including in-vitro drug release studies of all formulations. Out of all 
formulations the one prepared with combination of sodium alginate and Kollidon SR has the release of drug over 12 hrs. 
The in-vitro release data was fitted to different kinetic models which showed highest regression for zero order kinetics with 
higuchi mechanism. [20]    
              Himabindu et al designed bilayer tablets of Quinapril Hydrochloride. In this work the tablets were formulated using 
direct compression technology by employing polymers like Sodium alginate, Cekol 30000 and Kollidon SR in sustained 
release layer and crospovidone was used as super disintegrant along with other excipients. The drug-excipient compatible 
studies were performed by FTIR. The study revealed that there is no drug-excipient interaction. The prepared bilayered 
tablets were evaluated for various physicochemical parameters including invitro drug release studies of all formulations. 
Out of all formulations the one prepared with combination of sodium alginate and Kollidon SR has the release of drug over 
12 hrs. The in-vitro release data was fitted to different kinetic models which showed highest regression for zero order 
kinetics with higuchi mechanism. [21] 
             Ghorpade et al designed the gastro-retentive floating drug delivery system containing antihypertensive drug. The 
floating drug delivery system can remain in the gastric region for several hours via float on the gastric contents and hence 
significantly prolong the gastric residence time of drugs. In the recent years, scientific and technological advancement have 
been made in the research and developed of novel drug delivery system. By overcoming physiological troubles such as short 
gastric residence time and unpredictable gastric emptying times, oral route is the most preferable route of administration but 
it has certain limitation for those drugs which absorb from upper part of GI tract or having narrow absorption window. The 
bioavailability of these drugs by increasing the residence of the dosage form in the stomach. The gastric residence time of 
the dosage form can be improved by formulating them as floating drug delivery system. The current and recent development 
of stomach specific antihypertensive drug formulated as floating drug delivery system is discussed in this review. [22] 
 
2. Conclusion 
          To achieve the prolong effect in hypertension i.e. antihypertensive, the drug availability must be ensured in the body. 
The gastro retentive floating system prolongs release formulations attempted with different investigators mentioned above 
may be used commercially. Quinapril HCl gastro retentive floating tablets may be formulated with different polymers at 
various concentrations. With gastro retentive floating prolong release drug delivery system reduced frequency of dosing or 
increase effectiveness of the drug by localization at the site of action or enhanced bioavailability and uniform drug release 
may be achieved. Hence it also improves the patient convenience and compliance. 
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